San Mateo, CA – According to filings with the U.S. Securities and Exchange Commission, BigHat Biosciences is raising $80,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Mark Depristo played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About BigHat Biosciences
BigHats mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or wet lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from todays most challenging diseases. BigHat is backed by Section 32, Andreessen Horowitz, 8VC, Amgen Ventures, Bristol Myers Squibb, Quadrille, Grids Capital, AME Cloud Ventures, Innovation Endeavors and Gaingels.

To learn more about BigHat Biosciences, visit http://www.bighatbio.com/

Contact:
Mark Depristo, Chief Executive Officer
857-928-5232
https://www.linkedin.com/in/markdepristo/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved